Does Blue Cross Blue Shield of Michigan Cover Semaglutide (Wegovy)?

What Wegovy Is and Why Coverage Is Complicated

Semaglutide 2.4 mg (Wegovy) is a once-weekly GLP-1 receptor agonist approved by the FDA on June 4, 2021, specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. [1] Its mechanism, slowing gastric emptying and reducing appetite through GLP-1 receptor activation, is the same class used in the diabetes drug Ozempic (semaglutide 1 mg/2 mg), but Wegovy carries a distinct FDA approval for obesity.

Coverage is complicated because federal law does not require commercial insurers to cover obesity medications. The Affordable Care Act mandates coverage of obesity counseling but not pharmacotherapy. That gap has left each insurer, including BCBSM, to set its own formulary rules.

Clinical Efficacy That Insurers Cannot Ignore

In the STEP-1 trial (N=1,961), participants receiving semaglutide 2.4 mg achieved a mean body weight loss of 14.9% at 68 weeks, compared with 2.4% in the placebo group (P<0.001). [2] The SELECT cardiovascular outcomes trial (N=17,604) later demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE) among adults with established cardiovascular disease and overweight or obesity, without diabetes. [3] That SELECT finding became the foundation for expanded Medicare Part D coverage discussions and for many commercial payers reconsidering their obesity drug restrictions.

How BCBSM Classifies Wegovy on the Formulary

BCBSM places Wegovy on a specialty tier (typically Tier 4 or Tier 5) on most commercial plans. Specialty-tier drugs carry the highest cost-sharing before deductible is met. Once prior authorization is approved and the deductible is satisfied, a 30-day supply may cost $25, $200 depending on the specific plan design. Members on High Deductible Health Plans (HDHPs) pay the full negotiated rate until their deductible threshold is reached.

BCBSM Prior Authorization Criteria for Wegovy

Prior authorization (PA) is required for semaglutide 2.4 mg on virtually all BCBSM commercial and Medicare Advantage plans. Approval generally requires meeting all of the following criteria simultaneously.

Body Mass Index Requirements

The BMI standard mirrors FDA labeling directly. A member must have a documented BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher combined with at least one weight-related comorbidity. [1] Qualifying comorbidities listed in most BCBSM PA criteria include type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea (OSA), and nonalcoholic steatohepatitis (NASH). BMI must be documented in the medical record within the preceding 12 months, not self-reported.

Lifestyle Intervention Documentation

BCBSM typically requires evidence that a member participated in a structured diet and exercise program for at least three to six months prior to the PA request. Acceptable documentation includes chart notes from a primary care physician or obesity medicine specialist, enrollment records from a structured weight management program, or referrals to a registered dietitian. A single self-reported attempt usually does not satisfy this criterion.

Step Therapy Requirements

Many BCBSM plan variants include a step therapy requirement, meaning a member must first try and fail at least one other FDA-approved weight-loss medication at an adequate dose and duration before Wegovy is approved. Agents commonly listed as required first steps include orlistat 120 mg (Xenical) and phentermine/topiramate extended-release (Qsymia). Failure is defined as less than 5% body weight loss after 12 weeks at therapeutic dose, or intolerance documented by the prescribing clinician.

Prescriber Specialty

Some BCBSM plan documents specify that PA requests carry more weight when submitted by an internal medicine physician, endocrinologist, or obesity medicine specialist (Diplomat of the American Board of Obesity Medicine). A primary care prescriber can submit, but supplementing the request with a specialist note may reduce denial rates.

How to Get Prior Authorization Approved: Step-by-Step

Getting a PA approved for Wegovy through BCBSM is a process that rewards documentation. Incomplete submissions are the single most common reason for initial denial.

Step 1: Confirm Your Plan's Formulary

Call the member services number on your insurance card or log into the BCBSM member portal to confirm whether Wegovy appears on your plan's formulary for the current benefit year. Formularies change on January 1 each year. A drug covered in 2024 may be on a different tier or carry new restrictions in 2025.

Step 2: Have Your Prescriber Gather Clinical Documentation

Your physician should compile at minimum: two or more BMI measurements with dates, ICD-10 diagnosis codes for obesity (E66.01 for morbid obesity due to excess calories, or E66.09 for other obesity), documentation of the comorbidity if BMI is 27 to 29.9, records of at least one structured lifestyle program, and any prior weight-loss medication trials with dates and outcomes.

Step 3: Submit the PA Request With a Letter of Medical Necessity

A Letter of Medical Necessity (LMN) written by the prescriber and citing specific clinical criteria is not required, but it substantially improves approval rates. The LMN should reference the STEP-1 trial data [2] and, where applicable, the SELECT trial cardiovascular outcomes [3] to establish that pharmacotherapy is medically appropriate, not merely cosmetic. The Obesity Medicine Association recommends framing obesity as a chronic, relapsing disease, consistent with the American Medical Association's 2013 recognition of obesity as a disease. [4]

Step 4: If Denied, File a Level 1 Appeal Within 60 Days

BCBSM must acknowledge a Level 1 appeal within 72 hours for urgent cases or 30 days for standard appeals. Nationally, roughly 40 to 60% of initially denied specialty drug appeals are overturned when the appeal includes additional clinical documentation. [5] Include peer-reviewed evidence such as the STEP-1 [2] and SELECT [3] publications directly in the appeal package.

Step 5: External Review if Level 1 Fails

Michigan law (MCL 550.1901 et seq.) grants members the right to an independent external review by a state-certified Independent Review Organization (IRO) if internal appeals fail. The IRO's decision is binding on the insurer.

Medicare Advantage and Medicare Part D Coverage Through BCBSM

Traditional Medicare historically excluded weight-loss drugs under Part D due to a statutory exclusion dating to 2003. That exclusion has been partially addressed. [6]

The SELECT Trial and Cardiovascular Indication

The SELECT trial (N=17,604) results, published in the New England Journal of Medicine in 2023, showed semaglutide 2.4 mg reduced MACE by 20% (hazard ratio 0.80, 95% CI 0.72 to 0.90, P<0.001) in adults with cardiovascular disease and overweight without diabetes. [3] The FDA subsequently approved a cardiovascular risk reduction indication for Wegovy in March 2024. [7] That new indication opened a pathway for Medicare Part D coverage of Wegovy for members with established CVD, coverage that CMS confirmed would begin in January 2026 for qualifying beneficiaries.

BCBSM Medicare Advantage plans follow CMS guidance on this point. Members with BCBSM Medicare Advantage who have documented cardiovascular disease and a qualifying BMI should ask their prescriber to document the cardiovascular indication (ICD-10 I25.10 or similar) explicitly on the PA request.

Medicaid Coverage in Michigan

Michigan Medicaid (Healthy Michigan Plan) covers semaglutide 2.4 mg with PA for qualifying members. The Medicaid PA criteria generally mirror commercial criteria, BMI ≥30 or BMI ≥27 with comorbidity, documented lifestyle intervention, and prescriber documentation. Members should verify current preferred drug list (PDL) status through the Michigan Department of Health and Human Services.

What Semaglutide Actually Costs in Michigan Without Coverage

Without insurance, the wholesale acquisition cost (WAC) for Wegovy in 2024 is approximately $1,349 per 28-day supply (four auto-injector pens), set by Novo Nordisk. [8] Over a full year, that totals roughly $16,188 before any discounts.

Novo Nordisk Patient Assistance and Savings Programs

Novo Nordisk offers the Wegovy Savings Card for commercially insured patients, which may reduce out-of-pocket costs to as low as $25 per 28-day fill for eligible members. Eligibility restrictions apply, the card cannot be used by Medicare or Medicaid beneficiaries. The NovoCare Patient Assistance Program provides Wegovy at no cost to uninsured patients who meet income requirements (generally at or below 400% of the federal poverty level). Applications are processed at novonordisk-us.com/patients.

Compounded Semaglutide: An Important Caution

During the 2022 to 2024 Wegovy shortage, the FDA allowed 503A and 503B compounding pharmacies to produce semaglutide. The FDA removed semaglutide from its drug shortage list in October 2024, meaning compounded semaglutide is no longer legally permitted under federal outsourcing exemptions. [9] The FDA has stated explicitly that compounded semaglutide products are not FDA-approved and may carry safety risks related to incorrect dosing or contamination. [9] BCBSM does not cover compounded semaglutide under any plan.

How Wegovy Compares to Other Covered Weight-Loss Drugs on BCBSM Plans

Understanding where Wegovy sits relative to alternatives helps members and prescribers choose the path of least insurance resistance when step therapy is required.

| Drug | Generic Available | Typical BCBSM Tier | Mean Weight Loss (Trial) | FDA Obesity Approval | |---|---|---|---|---| | Orlistat 120 mg (Xenical) | Yes (orlistat) | Tier 1 to 2 | ~3% at 1 year [10] | 1999 | | Phentermine/topiramate ER (Qsymia) | No | Tier 3 to 4 | ~8.9% at 56 weeks [11] | 2012 | | Naltrexone/bupropion (Contrave) | No | Tier 3 to 4 | ~5.4% at 56 weeks [12] | 2014 | | Liraglutide 3 mg (Saxenda) | No | Tier 4 (specialty) | ~5.8% at 56 weeks [13] | 2014 | | Semaglutide 2.4 mg (Wegovy) | No | Tier 4 to 5 (specialty) | ~14.9% at 68 weeks [2] | 2021 | | Tirzepatide 15 mg (Zepbound) | No | Tier 4 to 5 (specialty) | ~20.9% at 72 weeks [14] | 2023 |

Prescribers arguing against step therapy for semaglutide can point to the magnitude of the efficacy difference: the 14.9% mean weight loss in STEP-1 [2] is roughly 2.5-fold greater than orlistat's 3% result [10], and that gap has clinical relevance for patients with obesity-related hypertension or pre-diabetes.

Employer-Sponsored Plans vs. Individual Marketplace Plans

BCBSM sells coverage through two main channels in Michigan: employer-sponsored group plans and individual/family plans through the federal Marketplace (healthcare.gov). Coverage rules differ.

Employer-sponsored plans are governed by ERISA (for self-funded plans) or state insurance law (for fully-insured plans). Self-funded plans, common at large Michigan employers, can exclude weight-loss drugs entirely regardless of BCBSM's standard formulary. About 65% of covered workers nationally are in self-funded plans. [15] If your HR department tells you weight-loss drugs are excluded, that exclusion may be in the plan document itself, not the formulary, and it cannot be appealed through standard channels.

Individual Marketplace plans sold by BCBSM follow Michigan-specific formulary rules. These plans are more likely to include Wegovy coverage with PA than self-funded employer plans, because state insurance mandates apply to them.

Confirming whether your plan is fully-insured or self-funded is the first thing to do. Your HR benefits coordinator or the Summary Plan Description (SPD) document will specify this.

Documentation Checklist for Prescribers Submitting a PA

A prescriber submitting a Wegovy PA to BCBSM should include all of the following elements. Missing even one item is a common cause of automatic denial.

• Two or more dated BMI measurements from the medical record (not self-reported)
• ICD-10 obesity diagnosis code (E66.01, E66.09, or E66.8 as appropriate)
• ICD-10 comorbidity code if BMI is 27 to 29.9 (e.g., E11.9 for type 2 diabetes, I10 for hypertension)
• Dates, names, and outcomes of any prior weight-loss medication trials
• Documentation of structured lifestyle intervention (program name, duration, provider)
• Letter of Medical Necessity citing BMI, comorbidities, prior treatment failure, and published clinical evidence
• Prescriber NPI and DEA number on all paperwork
• Contact information for peer-to-peer review if BCBSM medical director requests a call

The American Association of Clinical Endocrinology (AACE) 2022 obesity guidelines state: "Pharmacotherapy should be considered for all patients with obesity who have not achieved clinically meaningful weight loss through lifestyle intervention alone." [16] Quoting that guideline directly in the LMN gives the PA reviewer an external clinical anchor for the approval decision.